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Summary
The granulation pattern of somatotroph adenomas is well known to be associated with differing clinical and biochemical 
characteristics, and it has been shown that sparsely granulated tumours respond poorly to commonly used somatostatin 
receptor ligands (SRLs). We report a challenging case of acromegaly with a sparsely granulated tumour resistant to 
multiple modalities of treatment, ultimately achieving biochemical control with pasireotide. A 26-year-old lady presented 
with classical features of acromegaly, which was confirmed by an oral glucose tolerance test. Insulin-like growth factor 1 
(IGF1) was 1710 µg/L (103–310 µg/L) and mean growth hormone (GH) was >600 U/L. MRI scan showed a 4 cm pituitary 
macroadenoma with suprasellar extension and right-sided cavernous sinus invasion. She underwent trans-sphenoidal 
pituitary surgery. Histology displayed moderate amounts of sparsely granular eosinophilic cytoplasm, staining only for 
GH. Postoperative investigations showed uncontrolled disease (IGF1:1474 µg/L, mean GH:228 U/L) and residual tumour in 
the cavernous sinus. She received external beam fractionated radiation. Over the years, she received octreotide LAR (up 
to 30 mg), lanreotide (up to 120 mg) two weekly, cabergoline, pegvisomant and stereotactic radiosurgery to no avail. Only 
pegvisomant resulted in an element of disease control; however, this had to be stopped due to abnormal liver function 
tests. Fifteen years after the diagnosis, she was started on pasireotide 40 mg monthly. Within a month, her IGF1 dropped 
and has remained within the normal range (103–310 µg/L). Pasireotide has been well tolerated, and there has been 
significant clinical improvement. Somatostatin receptor subtyping revealed a positivity score of two for both sst5 and 
sst2a subtypes.
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Learning points:
 • Age, size of the tumour, GH levels on presentation, histopathological type and the somatostatin receptor status 
of the tumour in acromegaly should be reviewed in patients who poorly respond to first-generation somatostatin 
receptor ligands.
 • Tumours that respond poorly to first-generation somatostatin receptor ligands, especially sparsely granulated 
somatotroph adenomas, can respond to pasireotide and treatment should be considered early in the management 
of resistant tumours.
 • Patients with membranous expression of sst5 are likely to be more responsive to pasireotide.
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Background
Morbidity and mortality rates of uncontrolled acromegaly 
are much higher than those of the general population. 
However, adequate biochemical control reverses 
mortality rates. Currently, medical therapy is becoming 
an important part of the treatment of patients with 
acromegaly. Long-acting formulations of octreotide 
and lanreotide, first-generation somatostatin receptor 
ligands (SRLs), that mainly bind to receptor sst2, remain 
the standard medical therapy and play an important 
role when either surgery is ineffective or as a first-line 
therapy when surgery is contraindicated. Pasireotide is 
a somatostatin receptor ligand, acting on receptors sst1, 
sst2, sst3 and sst5 and has recently been approved for 
the treatment of acromegaly. The granulation pattern of 
somatotroph adenomas is well known to be associated 
with differing clinical and biochemical characteristics, 
and it has been shown that sparsely granulated tumours 
respond poorly to first-generation somatostatin receptor 
ligands. We report a challenging case of acromegaly due 
to a sparsely granulated pituitary adenoma, resistant 
to multiple modalities of treatment administered over 
several years and ultimately achieving biochemical 
control with pasireotide.
Case presentation
A 26-year-old lady presented with tiredness, progressive 
enlargement of hands and feet, secondary amenorrhoea, 
gradually worsening headache together with excessive 
sweating for three years. There was no family history 
of pituitary tumours, hypercalcaemia or renal stones. 
Examination revealed typical features of acromegaly. Her 
blood pressure and visual fields were normal.
Investigations
The oral glucose tolerance test (OGTT) was performed to 
confirm the diagnosis of acromegaly (nadir GH: 772 U/L). 
Her IGF-1 level was 1710 µg/L (103–310 µg/L). A growth 
hormone day curve was performed to assess the disease 
burden, and it highlighted the presence of severe disease 
(mean GH >600 U/L). Other anterior pituitary hormone 
testing showed secondary hypogonadism (LH <0.5 IU/L 
(2.4–13 IU/L), FSH <0.37 IU/L (3.5–13 IU/L), oestradiol 
<50 pmol/L (91.8–854 pmol/L), elevated prolactin of 
796 U/L (102–496 U/L)) and hypothyroidism (TSH: 10.8 IU/L 
(0.27–4.2 IU/L), free T4 of 6 pmol/L (12–22 pmol/L)). 
MRI scan showed a 4 × 2 × 3 cm pituitary macro adenoma 
with suprasellar extension and right-sided cavernous 
sinus invasion.
Treatment
The patient underwent trans-sphenoidal surgery 
of the pituitary tumour in 1999. Histology of the 
excised specimen revealed moderate amounts of 
finely (sparsely) granular eosinophilic cytoplasm. 
Immunohistochemistry was positive for growth 
hormone but negative for other pituitary hormones. 
Ki 67 index was <1%.
Her postoperative IGF1 was 1474 µg/L and mean 
GH was 228 U/L, indicating uncontrolled disease. Post-
operative MRI of the pituitary revealed residual tumour 
in the cavernous sinus and close to the optic chiasm. 
Therefore, external beam fractionated radiation was given 
five months after surgery.
Octreotide treatment was initiated postoperatively, as 
20 mg every 4 weeks. It was then increased stepwise, up 
to 30 mg every two weeks. The lowest IGF1 achieved was 
1065 µg/L indicating partial resistance. Octreotide was 
stopped in September 2004.
Due to the persistent elevation of biochemical 
markers over four years following surgery, she was 
started on pegvisomant, which resulted in reasonable 
disease control. Her IGF-1 levels came down from above 
1000 to 340 µg/L. Within a few months of pegvisomant 
therapy, there was a positive clinical response; however, 
she developed abnormal liver function tests necessitating 
discontinuation of the treatment. She was re-challenged 
with pegvisomant, but in view of a recurrent rise in liver 
enzymes, treatment was stopped.
Lanreotide was initiated in January 2005 as 120 mg 
monthly and was soon increased to twice weekly. In April, 
cabergoline 0.5 mg twice a week was added to lanreotide, 
but it was stopped in 2006 as it did not have a positive 
impact on disease control. In 2010, the patient developed 
diarrhoea and the lanreotide frequency was reduced 
back to once a month. In 2010, patient had stereotactic 
radio surgery targeting residual tumour within the 
cavernous sinuses.
Lanreotide was stopped in 2013 as the patient 
underwent a clinical trial with antisense, a form of siRNA 
treatment. Antisense was not able to control the disease 
and following the trial, she went back to lanreotide 
treatment with an IGF-1 of 1258 µg/L. She was on 
lanreotide till October 2015.
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Over fifteen years, no treatment was able to control 
the disease burden, and the patient remained highly 
symptomatic with headaches, fatigue and osteoarthritis. 
In 2015, the patient was started on pasireotide 40 mg 
monthly. Figure  1 shows her clinical therapy and 
hormone levels.
Outcome and follow-up
Within a month of starting pasireotide 40 mg monthly, 
her IGF-1 levels dropped to the normal range and 
have remained within the normal range for age 
(103–310 µg/L) over 15  months although her tumour 
size has not changed. Late effects of radiotherapy may 
also have contributed to the normalization of GH and 
IGF-1. Pasireotide remains well tolerated and has not 
been complicated by glucose intolerance. Her HBA1c 
was closely monitored and values ranged from 41 to 
44 mmol/mol. It was 42 mmol/mol prior to starting 
pasireotide. The patient’s symptoms have significantly 
improved, and she is now back to work. Somatostatin 
receptor (sst) sub typing revealed positivity for sst5 and 
sst2a subtypes (Fig. 2).
Discussion
Despite availability of multiple treatment modalities, 
acromegaly sometimes is a challenging condition to treat, 
and we report a patient whose disease was only controlled 
with pasireotide. The patient had a sparsely granulated 
tumour with suprasellar extension and invasion of the 
cavernous sinus, and these tumours are known to be more 
difficult to control. Sparsely granulated somatotroph 
adenomas are commoner among young females, are 
generally larger than densely granulated somatotroph 
adenomas, less responsive to somatostatin receptor 
ligands (1, 2) and more frequently reported to have 
suprasellar extension and cavernous sinus infiltration (3).
A number of factors in our patient are associated 
with increased resistance to treatment of acromegaly. 
Preoperative GH levels are an important predictor of 
remission in acromegaly (4). Extremely high disease 
burden is indicated by clinical findings, biochemistry and 
imaging and could have contributed largely to the poor 
response to initial treatment in our patient.
The response to somatostatin receptor ligands depends 
on the expression of the somatostatin receptor subtype (5). 
Pasireotide is a somatostatin receptor ligand recently 
Figure 1
The graph illustrates the relationship between 
different modalities of clinical therapy with 
IGF 1 levels.
Figure 2
(A) Immunohistochemistry for sst2a showing 
membranous expression of sst2a (score 2 according 
to scoring system proposed by Volante et al. (9)). 
The staining was performed using the monoclonal 
UMB-1 (Abcam) on an automated Ventana system. 
(B) Immunohistochemistry for sst5 showing 
membranous expression of sst5 (score 2 according 
to scoring system proposed by Volante et al. (9)). 
The staining was performed using the monoclonal 
UMB-4 (Abcam) on an automated Ventana system.
pW K M G Amarawardena 
and others
Pasireotide: in a resistant case 
of acromegaly
ID: 17-0067; July 2017
DOI: 10.1530/EDM-17-0067
http://www.edmcasereports.com 4
approved for the treatment of acromegaly. Randomised 
studies have shown its superiority to octreotide 
and lanreotide in the treatment of uncontrolled 
acromegaly (6). In contrast to octreotide and lanreotide, 
which bind preferentially to somatostatin receptor 
sst2, pasireotide has a binding affinity for sst5 that is 
approximately 39- and 106-fold higher and a lower 
binding affinity for sst2 (approximately 0.4- and 
0.5-times lower) (7). A small retrospective study of eleven 
patients resistant to first-generation SRLs were treated 
with pasireotide, and it was found that the expression of 
sst5 could predict the responsiveness to treatment (8). The 
study also showed that sparsely granulated somatotroph 
adenomas responded to pasireotide better than densely 
granulated tumours. Sparsely granulated tumours had 
a tendency for a lower sst2a expression compared to 
densely granulated somatotroph adenomas, but no 
difference was observed for sst5 expression. The study 
concluded that this somatostatin receptor profile might 
explain the better responsiveness of sparsely granulated 
tumours to pasireotide. Our patient had a sparsely 
granulated tumour, which stained for both sst2a as well 
as sst5 using the rabbit monoclonal antibodies (Abcam) 
on the automated Ventana system. The membranous 
expression of somatostatin receptor is a prerequisite for 
the responsiveness to different somatostatin receptor 
ligands (8). Patients with negative or only cytoplasmic 
sst5 expression (scores 0–1 according to the scoring 
system proposed by Volante et al.) (9) are sometimes not 
considered responsive to pasireotide as opposed to cases 
with membranous expression of sst5 (scores 2 or 3 in 
the same scoring system) according to Volante et al. Our 
patient shows positive expression for both sst2a and sst5 
with a score of 2 (i.e. membranous staining in <50% of 
cells or incomplete membranous staining), explaining the 
good response to pasireotide.
Studies revealed that the tolerability profile of intra-
muscular pasireotide is generally similar to that of first-
generation agents, except for a higher incidence of 
hyperglycaemia-related adverse events with pasireotide, 
suggesting the importance of careful monitoring of 
glycaemic status (10). Pasireotide was well tolerated in our 
patient, and she has not developed hyperglycaemia for a 
follow-up period of 15 months.
Pasireotide should be considered early in tumours that 
respond poorly to first-generation somatostatin receptor 
ligands, especially sparsely granulated somatotroph 
adenomas with membranous expression of sst5.
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